Herpes Zoster Medication
- Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD more...
Whereas there were once no effective therapies for herpes zoster, the advent of oral antiviral agents has made the treatment of this condition possible. Acyclovir and its derivatives (famciclovir, penciclovir, and valacyclovir) have been shown to be safe and effective in the treatment of active disease and the prevention of postherpetic neuralgia (PHN). Low-dose gabapentin used in acute herpes zoster did not appear effective in preventing PHN. Other agents used in management include corticosteroids, analgesics, tricyclic antidepressants (TCAs), and vaccines.
Antiviral agents exert a direct antiviral effect on varicella-zoster virus (VZV). Nucleoside analogues initially are phosphorylated by viral thymidine kinase, eventually forming a nucleoside triphosphate. These molecules inhibit herpes simplex virus (HSV) polymerase with 30-50 times the potency of human alpha-DNA polymerase.
The goals of antiviral therapy for herpes zoster are to decrease pain, to inhibit viral replication and shedding, to promote healing of skin lesions, and to prevent or reduce the severity of postherpetic neuralgia. Antiviral therapy may decrease the length of time for new vesicle formation, the number of days to attain complete crusting, and the days of acute discomfort. Initiate treatment as soon as possible because treatment is most effective within 72 hours of eruption.
Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against human herpes viruses, including HSV type 1 (HSV-1), HSV-2, VZV, Epstein-Barr virus (EBV), and cytomegalovirus (CMV). In cell cultures, acyclovir has the highest antiviral activity against HSV-1, followed, in decreasing order of potency, by HSV-2, VZV, EBV, and CMV.
Treatment with acyclovir is indicated in patients with involvement of the first branch of the trigeminal nerve, those who are immunocompromised, or those with increased risk for major complications from a varicella infection (ie, patients older than 13 years, those receiving long-term corticosteroid or aspirin therapy, and those with chronic cutaneous or pulmonary diseases). Zoster in adolescents may be treated with oral acyclovir if it is initiated within 72 hours of eruption.
Famciclovir is a prodrug that, once ingested, is rapidly biotransformed into the active compound penciclovir and phosphorylated by viral thymidine kinase. By competition with deoxyguanosine triphosphate, penciclovir triphosphate inhibits viral polymerase. Activity against HSV-1, HSV-2, and VZV has been demonstrated.
Therapy should be initiated as soon as herpes zoster is diagnosed. No data are available on the efficacy of treatment started 72 hours after rash onset. The dosage should be adjusted in patients with renal insufficiency or hepatic disease.
Valacyclovir is an L-valyl ester of acyclovir. It is rapidly converted to acyclovir, which has demonstrated antiviral activity against HSV-1, HSV-2, VZV, and other viruses.
Therapy should be initiated at the earliest sign or symptom of herpes zoster; it is most effective when started within 48 hours of the onset of zoster rash. No data are available on the efficacy of treatment started 72 hours after rash onset.
Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. These agents modify the body’s immune response to diverse stimuli. Some authors find benefit in the short-term use of steroids to help manage herpes zoster, and some evidence exists to suggest a decreased incidence of PHN in patients who received steroids. Other studies find no benefit from the use of steroids.
Although steroid use is controversial in herpes zoster, it remains a therapeutic option. Prednisone is inactive and must be metabolized to the active metabolite prednisolone. Conversion may be impaired in patients with liver disease.
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and facilitate physical therapy. Most oral narcotic analgesics have sedating properties that are beneficial for patients who have skin lesions.
Oxycodone is a narcotic analgesic that is indicated for the relief of moderate to severe pain. Patients with herpes zoster usually experience pain. Antiviral and steroid therapies provide relatively minor relief of pain, and narcotic analgesics are often needed.
Acetaminophen is indicated for use in patients with mild pain or fever. It is the drug of choice for the treatment of pain in patients who (1) have documented hypersensitivity to aspirin or NSAIDs, (2) have upper gastrointestinal (GI) disease, or (3) are taking oral anticoagulants. Acetaminophen reduces fever via direct action on hypothalamic heat-regulating centers, which increases dissipation of body heat via vasodilation and sweating.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is the drug of choice for treatment of mild to moderately severe pain, if no contraindications exist. It inhibits inflammatory reactions and pain, probably by decreasing the activity of the enzyme cyclooxygenase and thereby, in turn, inhibiting prostaglandin synthesis. Ibuprofen is one of the few NSAIDs that are indicated for fever reduction.
Naproxen another NSAID that is commonly used for the relief of mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, an effect that results in a decrease of prostaglandin synthesis.
Topical analgesics containing capsaicin have been shown to be effective for temporary relief of neuropathic pain.
Capsaicin is derived from plants of the Solanaceae family. It is a transient receptor potential vanilloid-1 (TRPV1) agonist indicated for neuropathic pain associated with PHN. TRPV1 is an ion channel–receptor complex expressed on nociceptive skin nerve fibers. Topical capsaicin causes initial TRPV1 stimulation that may cause pain, followed by pain relief via a reduction in TRPV1-expressing nociceptive nerve endings. Neuropathic pain may gradually recur over several months, an event thought to be caused by TRPV1 nerve fiber reinnervation of the treated area.
Capsaicin is a TRPV1 agonist indicated for neuropathic pain associated with postherpetic neuralgia. Topical capsaicin causes initial TRPV1 stimulation that may cause pain, followed by pain relief via a reduction in TRPV1-expressing nociceptive nerve endings. Neuropathic pain may gradually recur over several months; this recurrence is thought to be caused by TRPV1 nerve fiber reinnervation of the treated area.
Vaccines, Live, Viral
Vaccines consist of attenuated microorganisms or cellular components, which act as antigens. VZV vaccines elicit active immunization to increase resistance to infection. Administration stimulates antibody production with specific protective properties.
Zostavax is a lyophilized preparation of the Oka/Merck strain of live, attenuated VZV. It has been shown to boost immunity against herpes zoster virus (shingles) in older patients. It has been shown to reduce the occurrence of shingles by about 50% in individuals older than 60 years, by 64% in those aged 60-69 years, and by 70% in subjects aged 50-59 years. It also slightly reduces pain compared with no vaccination in those who develop shingles. The vaccine is indicated for the prevention of herpes zoster in patients who have no contraindications.
Although they are most often used as antiepileptics, certain anticonvulsants are also effective for treating neuropathic pain.
Gabapentin is a membrane stabilizer, a structural analogue of the inhibitory neurotransmitter gamma-amino butyric acid (GABA), which paradoxically is thought not to exert an effect on GABA receptors. Gabapentin appears to exert its effect via the α2δ1 and α2δ2 auxiliary subunits of voltage-gated calcium channels. It is used to manage pain and provide sedation in neuropathic pain. Gabapentin is primarily used for the treatment of PHN. It has also been used to treatment the pain of acute zoster.
Pregabalin is a structural derivative of GABA. It binds with high affinity to the α2-δ site (a calcium channel subunit). In vitro, it reduces calcium-dependent release of several neurotransmitters, possibly by modulating calcium channel function. It is approved by the US Food and Drug Administration (FDA) for neuropathic pain associated with diabetic peripheral neuropathy or PHN and as adjunctive therapy in partial-onset seizures.
TCAs have been shown to play a role in the treatment of PHN.
Amitriptyline blocks the reuptake of norepinephrine and serotonin. It decreases pain by inhibiting spinal neurons involved in pain perception.
Desipramine is a tricyclic antidepressant that, of the first-generation TCAs, has the least adverse effects. These agents have been found to be effective in relieving PHN.
[Guideline] Dworkin RH, Johnson RW, Breuer J, Gnann JW, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1. 44 Suppl 1:S1-26. [Medline].
Blein C, Gavazzi G, Paccalin M, Baptiste C, Berrut G, Vainchtock A. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France. BMC Infect Dis. 2015 Aug 19. 15 (1):350. [Medline].
Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. 1997 Sep. 36(9):667-72. [Medline].
Pasqualucci A, Pasqualucci V, Galla F, De Angelis V, et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol Scand. 2000 Sep. 44(8):910-8. [Medline].
Kost RG, Straus SE. Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med. 1996 Jul 4. 335(1):32-42. [Medline].
Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc). 2005 Aug. 41(8):509-16. [Medline].
Irving G, Jensen M, Cramer M, Wu J, Chiang YK, Tark M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009 Mar-Apr. 25(3):185-92. [Medline].
Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. J Med Econ. 2016 Jan 25. 1-29. [Medline].
Ongkosuwito JV, Feron EJ, van Doornik CE, Van der Lelij A, Hoyng CB, La Heij EC, et al. Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci. 1998 Dec. 39(13):2659-65. [Medline].
Kumano Y, Manabe J, Hamamoto M, Kawano Y, Minagawa H, Fukumaki Y, et al. Detection of varicella-zoster virus genome having a PstI site in the ocular sample from a patient with acute retinal necrosis. Ophthalmic Res. 1995. 27(5):310-6. [Medline].
Karlin JD. Herpes zoster ophthalmicus: the virus strikes back. Ann Ophthalmol. 1993 Jun. 25(6):208-15. [Medline].
Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore). 1983 Mar. 62(2):81-97. [Medline].
Pevenstein SR, Williams RK, McChesney D, Mont EK, Smialek JE, Straus SE. Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol. 1999 Dec. 73(12):10514-8. [Medline]. [Full Text].
Pavan-Langston D. Herpes zoster ophthalmicus. Neurology. 1995 Dec. 45(12 Suppl 8):S50-1. [Medline].
Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005 Dec. 118(12):1416. [Medline].
Norman J, Politz D. Shingles (varicella zoster) outbreaks in patients with hyperparathyroidism and their relationship to hypercalcemia. Clin Infect Dis. 2008 May 1. 46(9):1452-4. [Medline].
Chronister CL. Review of external ocular disease associated with aids and HIV infection. Optom Vis Sci. 1996 Apr. 73(4):225-30. [Medline].
Foster RE, Petersen MR, Neuss MN, Osher RH. Progressive outer retinal necrosis syndrome in a lymphoma patient with good visual outcome. Am J Ophthalmol. 2001 Jul. 132(1):117-20. [Medline].
Hodge WG, Seiff SR, Margolis TP. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology. 1998 May. 105(5):895-900. [Medline].
Kezuka T. Immune deviation and ocular infections with varicella zoster virus. Ocul Immunol Inflamm. 2004 Mar. 12(1):17-24. [Medline].
Margolis TP, Milner MS, Shama A, Hodge W, Seiff S. Herpes zoster ophthalmicus in patients with human immunodeficiency virus infection. Am J Ophthalmol. 1998 Mar. 125(3):285-91. [Medline].
Peck R, Gimple SK, Gregory DW, Youree B. Progressive outer retinal necrosis in a 73-year-old man: treatment with valganciclovir. AIDS. 2003 May 2. 17(7):1110-1. [Medline].
Purdy KW, Heckenlively JR, Church JA, Keller MA. Progressive outer retinal necrosis caused by varicella-zoster virus in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. 2003 Apr. 22(4):384-6. [Medline].
Rao NA. Acquired immunodeficiency syndrome and its ocular complications. Indian J Ophthalmol. 1994 Jun. 42(2):51-63. [Medline].
Walton RC, Reed KL. Herpes zoster ophthalmicus following bone marrow transplantation in children. Bone Marrow Transplant. 1999 Jun. 23(12):1317-20. [Medline].
Yau TH, Butrus SI. Presumed bilateral herpes zoster ophthalmicus in an AIDS patient: a case report. Cornea. 1996 Nov. 15(6):633-4. [Medline].
Bert RJ, Samawareerwa R, Melhem ER. CNS MR and CT findings associated with a clinical presentation of herpetic acute retinal necrosis and herpetic retrobulbar optic neuritis: five HIV-infected and one non-infected patients. AJNR Am J Neuroradiol. 2004 Nov-Dec. 25(10):1722-9. [Medline].
Gariano RF, Berreen JP, Cooney EL. Progressive outer retinal necrosis and acute retinal necrosis in fellow eyes of a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 2001 Sep. 132(3):421-3. [Medline].
Neves RA, Rodriguez A, Power WJ, Muccioli C, Lane L, Belfort R Jr, et al. Herpes zoster peripheral ulcerative keratitis in patients with the acquired immunodeficiency syndrome. Cornea. 1996 Sep. 15(5):446-50. [Medline].
Fernandes NF, Malliah R, Stitik TP, Rozdeba P, Lambert WC, Schwartz RA. Herpes zoster following intra-articular corticosteroid injection. Acta Dermatovenerol Alp Panonica Adriat. 2009 Mar. 18(1):28-30. [Medline].
Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol. 2003 Apr. 135(4):551-3. [Medline].
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18. 301(7):737-44. [Medline].
Sharma A, Makrandi S, Modi M, Sharma A, Marfatia Y. Immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol. 2008 Nov-Dec. 74(6):619-21. [Medline].
Reuters Health. Increased Risk of Herpes Zoster With IBD, Study Confirms. Available at http://www.medscape.com/viewarticle/776280. Accessed: February 21, 2013.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Feb. 37(4):420-9. [Medline].
Nouri K, Ricotti CA Jr, Bouzari N, Chen H, Ahn E, Bach A. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol. 2006 Feb. 5(2):182-5. [Medline].
Korber A, Franckson T, Grabbe S, Dissemond J. Ambilateral reactivation of herpes zoster V2 following cataract operation of both eyes. J Eur Acad Dermatol Venereol. 2007 May. 21(5):712-3. [Medline].
Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014. 348:g2911. [Full Text].
Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008 Sep. 122(3):e744-51. [Medline].
Whitley RJ. Varicella-Zoster Virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practices of Infectious Diseases. 7th ed. New York, NY: Churchill Livingstone; 2010:1963-69.
Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 1. 347(5):340-6. [Medline].
Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998 Nov. 178 Suppl 1:S67-70. [Medline].
Araújo LQ, Macintyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes. 2007 Sep. 14 Suppl 2:40-4. [Medline].
Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2012 Dec 28. [Medline].
Nagasako EM, Johnson RW, Griffin DR, Elpern DJ, Dworkin RH. Geographic and racial aspects of herpes zoster. J Med Virol. 2003. 70 Suppl 1:S20-3. [Medline].
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001 May 15. 32(10):1481-6. [Medline].
Ertunç V, Dane S, Karakuzu A, Deniz O. Higher herpes zoster infection frequency in right-handed patients and more frequent appearance in the left body side of females. Acta Derm Venereol. 1997 May. 77(3):245. [Medline].
Tseng HF, Smith N, Marcy SM, Sy LS, Chao CR, Jacobsen SJ. Risk factors of herpes zoster among children immunized with varicella vaccine: results from a nested case-control study. Pediatr Infect Dis J. 2010 Mar. 29(3):205-8. [Medline].
Ono N, Sakabe A, Nakajima M. [Herpes zoster oticus-associated jugular foramen syndrome]. Brain Nerve. 2010 Jan. 62(1):81-4. [Medline].
Edgerton G. Herpes zoster ophthalmicus: a review of the literature. Arch Ophthalmol. 1945;34:40-62; 114-53.
Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med. 1997 Jun 9. 157(11):1209-13. [Medline].
Svozílková P, Ríhová E, Diblík P, Kuthan P, Kovarík Z, Kalvodová B. Varicella zoster virus acute retinal necrosis following eye contusion: case report. Virol J. 2005 Aug 31. 2:77. [Medline]. [Full Text].
Westenend PJ, Hoppenbrouwers WJ. [Fatal varicella-zoster encephalitis; a rare complication of herpes zoster]. Ned Tijdschr Geneeskd. 1998 Mar 21. 142(12):654-7. [Medline].
Fabian VA, Wood B, Crowley P, Kakulas BA. Herpes zoster brachial plexus neuritis. Clin Neuropathol. 1997 Mar-Apr. 16(2):61-4. [Medline].
Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol. 1997 Jul. 52(3):316-9. [Medline].
Hong JJ, Elgart ML. Gastrointestinal complications of dermatomal herpes zoster successfully treated with famciclovir and lactulose. J Am Acad Dermatol. 1998 Feb. 38(2 Pt 1):279-80. [Medline].
Cresswell F, Eadie J, Longley N, Macallan D. Severe Guillain-Barré syndrome following primary infection with varicella zoster virus in an adult. Int J Infect Dis. 2010 Feb. 14(2):e161-3. [Medline].
Shapiro JS. Does varicella-zoster virus infection of the peripheral ganglia cause Chronic Fatigue Syndrome?. Med Hypotheses. 2009 Nov. 73(5):728-34. [Medline].
Ogita S, Terada K, Niizuma T, Kosaka Y, Kataoka N. Characteristics of facial nerve palsy during childhood in Japan: frequency of varicella-zoster virus association. Pediatr Int. 2006 Jun. 48(3):245-9. [Medline].
Elkind MS, Hills NK, Glaser CA, Lo WD, Amlie-Lefond C, Dlamini N, et al. Herpesvirus Infections and Childhood Arterial Ischemic Stroke: Results of the VIPS Study. Circulation. 2016 Jan 26. [Medline].
Grose C. Biological Plausibility of a Link Between Arterial Ischemic Stroke and Infection with Varicella-Zoster Virus or Herpes Simplex Virus. Circulation. 2016 Jan 26. [Medline].
Koh MJ, Seah PP, Teo RY. Zosteriform herpes simplex. Singapore Med J. 2008 Feb. 49(2):e59-60. [Medline].
Patel GA, Siperstein RD, Ragi G, Schwartz RA. Zosteriform lymphangioma circumscriptum. Acta Dermatovenerol Alp Panonica Adriat. 2009 Dec. 18(4):179-82. [Medline].
Ozcan A, Senol M, Saglam H, Seyhan M, Durmaz R, Aktas E, et al. Comparison of the Tzanck test and polymerase chain reaction in the diagnosis of cutaneous herpes simplex and varicella zoster virus infections. Int J Dermatol. 2007 Nov. 46(11):1177-9. [Medline].
Kalpoe JS, Kroes AC, Verkerk S, Claas EC, Barge RM, Beersma MF. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation. Bone Marrow Transplant. 2006 Jul. 38(1):41-6. [Medline].
Böer A, Herder N, Blödorn-Schlicht N, Falk T. Herpes incognito most commonly is herpes zoster and its histopathologic pattern is distinctive!. Am J Dermatopathol. 2006 Apr. 28(2):181-6. [Medline].
Homsy J, Katabira E, Kabatesi D, Mubiru F e. Evaluating herbal medicine for the management of Herpes zoster in human immunodeficiency virus-infected patients in Kampala, Uganda. J Altern Complement Med. 1999 Dec. 5(6):553-65. [Medline].
Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA. 1970 Mar 9. 211(10):1681-3. [Medline].
Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 1. 125(5):376-83. [Medline].
Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis. 1998 Nov. 178 Suppl 1:S81-4. [Medline].
van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006 Jan 21. 367(9506):219-24. [Medline].
Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology. 2005 Aug 9. 65(3):444-7. [Medline].
Dworkin RH, Barbano RL, Tyring SK, Betts RF, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr. 142(3):209-17. [Medline].
Lin PL, Fan SZ, Huang CH, Huang HH, Tsai MC, Lin CJ, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med. 2008 Jul-Aug. 33(4):320-5. [Medline].
De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. Pain. 1996 Apr. 65(1):45-51. [Medline].
Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010 Nov 5. 11:85. [Medline]. [Full Text].
Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, et al. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29. 85(2A):84-9. [Medline].
Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994. 4(4):241-6. [Medline].
Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15. 123(2):89-96. [Medline].
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul. 39(7):1546-53. [Medline]. [Full Text].
Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994 Mar 31. 330(13):896-900. [Medline].
Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med. 2004 Sep-Oct. 29(5):454-61. [Medline].
Ahmed HE, Craig WF, White PF, Ghoname ES, Hamza MA, Gajraj NM, et al. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Anesth Analg. 1998 Oct. 87(4):911-4. [Medline].
Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010 Sep. 24(3):809-33. [Medline].
Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh CL, Walsh L, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. Valaciclovir International Zoster Assessment Group (VIZA). J Eur Acad Dermatol Venereol. 2000 Jan. 14(1):23-33. [Medline].
Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res. 2002 Jan-Feb. 30(1):56-65. [Medline].
Kubeyinje EP. Cost-benefit of oral acyclovir in the treatment of herpes zoster. Int J Dermatol. 1997 Jun. 36(6):457-9. [Medline].
Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes. 2007 Sep. 14(2):32-6. [Medline].
Balfour HH Jr, Bean B, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983 Jun 16. 308(24):1448-53. [Medline].
Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000 Aug. 107(8):1507-11. [Medline].
Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003 Apr 1. 36(7):877-82. [Medline].
Whitley RJ, Volpi A, McKendrick M, Wijck Av, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 2010 May. 48 Suppl 1:S20-8. [Medline].
Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain. 2008 Jan. 9(1 Suppl 1):S19-30. [Medline].
Rauck RL, Irving GA, Wallace MS, Vanhove GF, Sweeney M. Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies. J Pain Symptom Manage. 2012 Nov 10. [Medline].
Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007 Apr 18. CD004846. [Medline].
Gelb LD. Preventing herpes zoster through vaccination. Ophthalmology. 2008 Feb. 115(2 Suppl):S35-8. [Medline].
Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000 Nov 23. 343(21):1514-9. [Medline].
Paster Z, Morris CM. Treatment of the localized pain of postherpetic neuralgia. Postgrad Med. 2010 Jan. 122(1):91-107. [Medline].
Pavan-Langston D. Herpes zoster antivirals and pain management. Ophthalmology. 2008 Feb. 115(2 Suppl):S13-20. [Medline].
Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf. 2004. 27(15):1217-33. [Medline].
Evans RW, Lee AG. Herpes zoster ophthalmicus, ophthalmoplegia, and trauma. Headache. 2004 Mar. 44(3):286-8. [Medline].
Oxman MN, Levin MJ, Johnson GR, Schmader KE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2. 352(22):2271-84. [Medline].
Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010 Jul 15. 51(2):197-213. [Medline].
Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009 Nov. 28(11):954-9. [Medline].
Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010 Feb 1. 27(2):159-76. [Medline].
Caple J. Varicella-zoster virus vaccine: a review of its use in the prevention of herpes zoster in older adults. Drugs Today (Barc). 2006 Apr. 42(4):249-54. [Medline].
van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009 Feb 25. 27(9):1454-67. [Medline].
[Guideline] Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 Jun 6. 57:1-30; quiz CE2-4. [Medline].
Schmader K, Levin M, Gnann J, McNeil S, Vesikari T, et al. Efficacy, immunogenicity, safety, and tolerability of zoster vaccine (ZV) in subjects 50 to 59 years of age (Poster/Abstract). Infectious Diseases Society of America. The 48th Annual Meeting of the Infectious Diseases Society of America. 10-21-2010;Vancouver, British Columbia, Canada:Ref Type: Abstract: 3363.
Schmader KE, Oxman MN, Levin MJ, Johnson G, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15. 55(10):1320-8. [Medline].
Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Jun 22. 56:1-40. [Medline].
[Guideline] Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011 Jun 15. 83 (12):1432-7. [Medline].
[Guideline] Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15. 59 (2):147-59. [Medline].
[Guideline] Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb. 58 (3):309-18. [Medline].
[Guideline] Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004 Sep 28. 63 (6):959-65. [Medline].
[Guideline] Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep. 17 (9):1113-e88. [Medline].
[Guideline] Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011 Nov 11. 60 (44):1528. [Medline].
[Guideline] Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR, Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014 Aug 22. 63 (33):729-31. [Medline].
Lee EG, Lee HJ, Hyun DJ, Min K, Kim DH, Yoon MS. Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study. Dermatol Ther. 2016 Jan 22. [Medline].